AMMF’s Hybrid 2025 European Cholangiocarcinoma Conference

AstraZeneca are platinum sponsors of AMMF’s 2025 Cholangiocarcinoma Conference.

Advancing Towards Zero: AstraZeneca’s Commitment to Transforming Cancer Outcomes

At AstraZeneca, we envision a future where cancer no longer claims lives prematurely, significantly altering the landscape of cancer care for families.  Realising our ambition, where cancer is no longer a cause of death calls for innovative approaches and collaboration, including the need to address complex cancers like cholangiocarcinoma.

Despite advances, cholangiocarcinoma care still faces barriers, notably influenced by socioeconomic factors. According to the AMMF’s “Rethink Liver Cancer” white paper, By far the most common route to diagnosis for people with CCA is via an emergency presentation (50%).¹ Unfortunately, over half of patients receive no cancer-specific treatment, such as surgery or systemic therapy, leading to poor survival rates overall. There is a critical need for earlier detection and improved access to treatment.

Scientific progress is rapidly evolving, providing a clear path forward in the fight against cancer. By utilising emerging technologies, AstraZeneca aims to transform cancer diagnosis and treatment, drawing closer to the ultimate ambition of one day eliminating cancer as a cause of death. Our focus includes leveraging advanced medical technologies and innovative strategies to target hard-to-treat cancers.

Cancer: Project Zero is our framework – a ‘North Star – guiding our approach and inspiring transformation in how we address cancer. This initiative is not about setting unrealistic expectations but about driving significant advancements in cancer care. Together with leaders in oncology, AstraZeneca is working towards a future where cancer is no longer a cause of death, a vision that requires embracing emerging technologies and novel treatment modalities, such as precision medicine and AI-driven diagnostics.² Project Zero is an initiative created and funded by AstraZeneca UK.

Collaboration is at the heart of AstraZeneca’s strategy, as we partner with organisations like AMMF, the NHS and research institutions, to harness scientific breakthroughs and enhance patient outcomes. By sharing knowledge and resources, we empower healthcare systems to diagnose and treat cancers earlier and more effectively. Our Cancer: Project Zero ambition drives us to continually innovate and integrate cutting-edge research into our treatment paradigms. Committed to scientific excellence and community collaboration, we aspire to redefine cancer care, creating a future where survival rates are transformed, and no one is lost to cancer too soon.

To find out how we are working to achieve this, visit us at our stand during the AMMF conference and join our symposium on Thursday 8^th May at 13:40 BST. This symposium is organised and funded by AstraZeneca.

Project Zero is an initiative created and funded by AstraZeneca UK.

AstraZeneca is not responsible for the privacy policy of any third party websites

_{1.AMMF Rethink Liver Cancer 2023: Available at: https://ammf.org.uk/wp-content/uploads/2024/01/AMMF-Rethink-Liver-Cancer-White-Paper-Jan-20242023-DIGITAL.pdf Accessed April 2025.}

_{2.AstraZeneca. Cancer: Project Zero. Available at:  Cancer-Project-Zero-Summit-Complete-essay-compendium.pdf Accessed April 2025.}

Z4-73443
April 2025

AstraZeneca have supported AMMF’s 2025 Conference through a financial contribution only. They have not been involved in the content nor in any other aspect of the conference.